Using ultrasound to assess erectile dysfunction after prostate cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of vibroelastography, a noninvasive ultrasound technique, in evaluating tissue fibrosis alongside standard penile duplex Doppler ultrasound to assess erectile function recovery in patients who have undergone radical prostatectomy for prostate cancer. The goal is to determine if this combined approach provides additional insights into erectile dysfunction recovery. Participants will be monitored for their erectile function post-surgery to evaluate the utility of this method.

Why it matters

Who can join: the full rules

Inclusion criteria include:

* Age \> 40 years
* Clinically localized prostate cancer (American Urological Association Grade Groups 1-2; cT1c or cT2a-b; PSA \< 10) without clinic or imaging evidence of localized extra-prostatic or metastatic disease (i.e. AUA low and favorable intermediate risk prostate cancer)
* International Index of Erectile Function (IIEF) of ≥ 21 points at baseline (no or mild erectile dysfunction)
* Patient-expressed interest in consultation for sexual function (erectile function) preservation/ optimization
* Planned bilateral nerves-paring prostatectomy

Exclusion criteria include:

* Moderate or severe ED based in IIEF criteria (score \< 21)
* History of prior pelvic or penile surgery
* Current or prior androgen deprivation therapy
* Planned non-nerve sparing prostatectomy

Where it's running

• Mayo Clinic in Rochester
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Matthew J. Ziegelmann, M.D. — Mayo Clinic

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• Lower-dose radiation to parts of the prostate for some men with prostate cancer

  This study tests whether a smaller amount of radiation aimed at specific parts of the prostate can reduce side effects compared with giving the full prostate the same dose.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07635238

• Next-generation SABR for prostate cancer across Ireland

  This test uses focused high-dose stereotactic radiotherapy (SABR) with urethra-sparing, a rectal spacer, and nerve preservation for men with low-, intermediate-, or selected high-risk prostate cancer to try to control the tumor while reducing side effects.

  Recruiting at 2 sites Phase 2 Cancer Trials Ireland · Dublin, Leinster and 3 other locations · NCT07552168

• Focal HDR-Brachytherapy for Prostate Cancer

  This trial tests using targeted high-dose-rate brachytherapy to treat prostate cancer patients and see if it provides local control with fewer side effects.

  Recruiting Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07468903

• Shorter androgen deprivation in combination with radiation for high-risk prostate cancer

  Doctors are testing whether 6 months of hormone therapy with radiation works as well as 18 months, for men with high-risk prostate cancer.

  Recruiting Phase 2 University of California, San Diego · La Jolla, California · NCT07364071

• PSMA PET/CT plus MRI to find higher‑grade prostate cancer in men on active surveillance

  This study tries adding rhPSMA-7.3 (flotufolastat F18) PET/CT to standard mpMRI to see if it finds higher-grade prostate cancer in men on active surveillance.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07285057

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.